Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

nivolumab

Screenshot of first page of the PLSP
16th Apr 2026

A plain language summary looking at nivolumab + chemotherapy for Asian people with advanced/recurrent stomach or gastroesophageal cancer

28th Oct 2025

CheckMate 7FL trial: nivolumab versus placebo in estrogen-positive breast cancer treatment: plain language summary

n this article, we summarize results from the ongoing phase 3 CheckMate 76K clinical study published online in Nature Medicine in October 2023. The study goal was to learn whether nivolumab works as an adjuvant therapy (that is, helps to keep cancer from coming back when it is given after surgery) for stage 2 melanoma (skin cancer) that has not spread to other parts of the body. Nivolumab is an immunotherapy that activates a person's immune system so it can destroy cancer cells. In melanoma, staging describes the severity of the cancer. Melanoma staging ranges from 0 (very thin and confined to the upper layer of the skin) to 4 (spread to distant parts of the body), with earlier stages removed by surgery. The people in this study had stage 2 melanoma that had not spread to the lymph nodes or other organs in the body.
27th Feb 2024

A plain language summary looking at nivolumab that is given after stage 2B/2C melanoma is removed by surgery

12th Apr 2023

Plain Language Summary: the CheckMate 274 study, treatment of muscle-invasive urothelial cancer with nivolumab

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy